Insite Vision Corporation

Coopervision International Limited

Sun Pharmaceutical Industries Limited

Coopervision International Holding Company, LP

Erwin C Si

Lyle M Bowman

Jon R Polansky

Sheng-Wan Tsao

Nancy J Keir

Santosh K Chandrasekaran

John C Babcock

Subam Basuthkar Sundar Rao

Victoria Rogers

Yuwen Liu

Arthur Bradley

Stephen Pham

Kamran Hosseini

Yuan Ji

Inna Maltseva

Hyo Jeang Lee

Santosh K Chandrasekran

John G Babcock

A WS12-releasing contact lens is described as well as method of manufacturing the same. The WS12-releasing contact lens comprises a polymeric lens body and WS12 releasably adhered to the polymeric lens body, and releases from 0.05 μg to 0.5 μg WS12 after 1 hour in a release media or when worn by a human subject. The WS12-releasing contact lens can be comfortably worn by a symptomatic contact lens wearer and can increase the duration of comfortable lens wearing time and/or reduce lens awareness events and/or reduce contact lens dryness in a symptomatic contact lens wearer.

WS12-releasing contact lens

An oleic acid-releasing contact lens is described as well as method of manufacturing the same. The oleic acid-releasing contact lens contains oleic acid releasably adhered to the polymeric lens body, and releases from 2 μg to 25 μg oleic acid after 1 hour in a release media. The oleic acid-releasing contact lens can be comfortably worn by a symptomatic contact lens wearer, and can increase the duration of comfortable lens wearing time and/or reduce lens awareness events in a symptomatic contact lens wearer.

Oleic acid-releasing contact lens

A WS12-releasing contact lens is described as well as method of manufacturing the same. The WS12-releasing contact lens comprises a polymeric lens body and WS12 releasably adhered to the polymeric lens body. The amount of WS12 releasably adhered to the polymeric lens body provides a basal tear concentration in lens wearers of 2 μg/ml to 8 μg/ml WS12 after 30 minutes of lens wear. The WS12-releasing contact lens can be used to increase contact lens comfort, reduce eye fatigue, reduce sensations of ocular dryness and impart a pleasant, cooling sensation in the lens wearer without causing stinging or burning upon insertion.

A contact lens having an amount of at least one cooling agent and at least one TRPV1 inhibitor releasably adhered is described as well as method of manufacturing the same. The contact lens can be comfortably worn by contact lens wearers and can increase the duration of comfortable lens wearing time and/or reduce lens awareness events and/or reduce contact lens dryness in a symptomatic contact lens wearer and further can reduce or avoid any stinging/burning sensation when the contact lens is first used or a short time thereafter.

Contact lens

The disclosure provides compositions and systems for topical ophthalmic application, which include an aqueous mixture of bromfenac and flowable mucoadhesive polymer, for treating inflammation and inflammatory conditions of the eye.

Non-steroidal anti-inflammatory ophthalmic compositions

An ophthalmic composition for administration to an eye of a patient for the treatment of an ocular infection. The ophthalmic composition contains an &#x3b5;-polylysine (&#x3b5;PL) in an amount effective to treat or control or prevent the ocular infection.

Ophthalmic composition for the treatment of ocular infection

Methods and compositions for the prophylactic and therapeutic treatment of retinal disorders associated with neovascularization using topical ophthalmic compositions comprising hydroxamic acid matrix metalloproteinase inhibitors such as batimastat.

Methods and compositions for treating and inhibiting retinal neovascularization

The invention provides methods for stabilizing amino-substituted steroid therapeutic agents in topical ophthalmic and other pharmaceutical formulations using effective stabilizing amounts of lightly cross-linked carboxy-containing polymers; and methods for stabilizing and solubilizing amino-substituted steroid therapeutic agents in such pharmaceutical formulations using effective stabilizing amounts of lightly cross-linked carboxy-containing polymers and amounts of selected cyclodextrin derivatives sufficient to at least partially solubilize the therapeutic agents. The cyclodextrin derivatives are selected from the group consisting of the hydroxypropyl, hydroxyethyl, glucosyl, maltosyl and maltotriosyl derivatives of .beta.- and .gamma.-cyclodextrin. Stabilized and stabilized/solubilized pharmaceutical compositions adapted for various routes of administration are also described.

Stabilization of aminosteroids for topical ophthalmic and other

The invention provides methods for stabilizing amino-substituted steroid therapeutic agents in topical ophthalmic and other pharmaceutical formulations using effective stabilizing amounts of lightly cross-linked carboxy-containing polymers; Stabilized and stabilized/solubilized pharmaceutical compositions adapted for various routes of administration are also described.

Methods and compositions for preventing or treating ophthalmic diseases or disorders wherein an ophthalmically effective amount of the C.sub.20 through C.sub.26 aminosteroids of formula XI and their pharmaceutical, acceptable salts, hydrates or solvates is administered in an inert vehicle to arrest oxidation processes damaging to the eye.

Growing community of inventors

Alameda, CA, United States of America

Erwin C Si